Nebivololo Accord (Nebivolol Hydrochloride)

Nebivolo Accord, a selective β1‑adrenergic blocker, is employed in the management of cardiovascular disorders that involve elevated blood pressure or impaired cardiac function.

• Hypertension: lowers systolic and diastolic blood pressure to reduce cardiovascular risk.
• Chronic heart failure: improves left‑ventricular ejection fraction and symptoms in patients with reduced ejection fraction.
• Elderly patients with hypertension: provides effective blood pressure control with a favorable tolerability profile.

• Nebivolol selectively antagonizes β1‑adrenergic receptors, decreasing heart rate and myocardial contractility, which reduces cardiac output and peripheral resistance. In addition, it stimulates endothelial nitric oxide synthase, enhancing nitric oxide release and causing vasodilation, further contributing to lowered blood pressure and improved vascular compliance.

Nebivolo Accord may cause a range of adverse reactions, some of which are more frequently observed than others.

Common Side Effects

• Headache: mild to moderate intensity.
• Dizziness or light‑headedness, especially on standing.
• Fatigue or tiredness during initial therapy.
• Nasal congestion or rhinorrhea.
• Gastrointestinal discomfort such as nausea or abdominal pain.
• Cold extremities: reduced peripheral circulation.

Serious or Rare Side Effects

• Bradycardia: markedly reduced heart rate requiring medical attention.
• Severe hypotension: sudden drop in blood pressure with risk of syncope.
• Acute heart failure decompensation.
• Bronchospasm in patients with reactive airway disease.
• Allergic reactions: rash, pruritus, or angioedema.

Before initiating Nebivolo Accord, clinicians should evaluate patient history and monitor for specific concerns.

• Renal impairment: adjust dose or monitor renal function.
• Hepatic dysfunction: use with caution and consider dose reduction.
• Diabetes mellitus: monitor blood glucose as β‑blockade may mask hypoglycaemia symptoms.
• Concomitant use with other antihypertensives: watch for additive blood pressure lowering.
• Pregnancy and lactation: safety not established; avoid unless clearly needed.
• Store at ambient temperature below 25°C: keep in original packaging, protect from moisture and light.

Nebivolo Accord can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Non‑selective β‑blockers: additive bradycardia and hypotension.
• Calcium channel blockers (verapamil, diltiazem): risk of severe bradycardia and AV block.
• Strong CYP2D6 inhibitors (e.g., paroxetine, fluoxetine): may increase nebivolol plasma levels.

Moderate Interactions (Monitor Closely)

• Diuretics: enhanced antihypertensive effect, monitor electrolytes.
• Antidiabetic agents: possible masking of hypoglycaemia signs.
• NSAIDs: may reduce antihypertensive efficacy.
• Antidepressants (tricyclics): potential for additive cardiac effects.